JBT Marel Corporation (JBTM)

NYSEIndustrialsIndustrial - MachinerySnapshot 2026-10-23

$108.59-1.00%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge JBT Marel Corporation’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.7%

+10% or more+5%0%−5%−10% or less

9.29 → 9.23 EPS · FY ending Dec 31, 2027 · 6 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.08B
EPS	—	2.395
FY 2026 · Annual
Revenue	$3.99B–$4.07B	4.01B
EPS	$4.2–$4.7GAAP $7.85–$8.35non-GAAP	8.029
EBITDA	$675M–$710Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	4.22B
EPS	—	9.229

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Implement $200M share repurchase program	The company is buying back $200 million of stock, showing strong capital allocation.	Intact	Share repurchase program is canceled or materially reduced	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. The Board authorized a $200 million share repurchase program effective May 18, 2026. During 2026-Q2, the Company repurchased approximately 200,000 shares for $26 million. The program is newly implemented and the trajectory is delivering initial repurchases. Delivery assessment Oct 24, 2026
Achieve $60M synergy cost savings in 2026	Synergy cost savings of $60 million support profitability.	Under Pressure	Synergy cost savings fall below $50 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The Company realized $43 million in synergy savings in 2025 and targets $60 million in 2026. Management reiterated the $60 million synergy savings target consistently, indicating ongoing execution with limited progress data but persistent focus. Delivery assessment Oct 24, 2026
EPS near $4.92 in 2026	Profit margins remain stable with EPS guidance near $4.92 for 2026.	Intact	EPS guidance midpoint falls below $4.7 in FY26	Diluted EPS: $0.54 per share FY2026-Q2; GAAP. Published target: ~$4.92 EPS. Target period is not explicitly aligned with this observation. Source published Aug 5, 20260.54 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8122b0e6-e4ff-4e17-b481-e6a4aac2dff7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Consolidated revenue growth of 5-7% in 2026	A primary condition in JBT Marel Corporation's published investment case. The stated target is 5-7% YoY growth.	Intact	YoY revenue growth falls below 5% in FY26	Revenue growth: 4.94% FY2026-Q2; GAAP. Published target: 5-7% YoY growth. Target period is not explicitly aligned with this observation. Source published Aug 5, 20264.942234 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8122b0e6-e4ff-4e17-b481-e6a4aac2dff7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew from $935 million in 2025-Q2 to $981 million in 2026-Q2 (+5%). Full year 2026 guidance reiterates expected revenue growth of 5-7% over 2025's $3.8 billion. The trajectory matches management's stated growth target and is delivering. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$9.23

$9.36 → $9.23 · observed estimates

FY2027 revenue$4.22B

$4.23B → $4.22B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$9.36	$4,225,182,493	5 / 5
2026-07-25	$9.36	$4,225,182,493	5 / 5
2026-07-26	$9.36	$4,225,182,490	6 / 6
2026-07-27	$9.36	$4,225,182,490	6 / 6
2026-07-28	$9.36	$4,225,182,493	5 / 5
2026-07-29	$9.36	$4,225,182,490	6 / 6
2026-07-30	$9.36	$4,225,182,490	6 / 6
2026-07-31	$9.36	$4,225,182,490	6 / 6
2026-08-01	$9.36	$4,225,182,493	5 / 5
2026-08-02	$9.36	$4,225,182,490	6 / 6
2026-08-03	$9.36	$4,225,182,490	6 / 6
2026-08-04	$9.36	$4,225,182,490	6 / 6
2026-08-05	$9.36	$4,225,182,490	6 / 6
2026-08-06	$9.36	$4,225,182,493	5 / 5
2026-08-07	$9.26	$4,225,575,876	5 / 5
2026-08-08	$9.26	$4,225,575,876	5 / 5
2026-08-09	$9.26	$4,225,575,880	6 / 6
2026-08-10	$9.26	$4,225,575,876	5 / 5
2026-08-12	$9.26	$4,225,575,876	5 / 5
2026-08-13	$9.25	$4,225,742,540	6 / 6
2026-08-14	$9.26	$4,225,575,876	5 / 5
2026-08-15	$9.26	$4,225,575,876	5 / 5
2026-08-16	$9.26	$4,225,575,876	5 / 5
2026-08-17	$9.26	$4,225,575,876	5 / 5
2026-08-18	$9.26	$4,225,575,876	5 / 5
2026-08-19	$9.26	$4,225,575,876	5 / 5
2026-08-20	$9.25	$4,225,742,543	5 / 5
2026-08-21	$9.25	$4,225,742,543	5 / 5
2026-08-22	$9.25	$4,225,742,543	5 / 5
2026-08-23	$9.25	$4,225,742,543	5 / 5
2026-08-24	$9.25	$4,225,742,543	5 / 5
2026-08-25	$9.25	$4,225,742,543	5 / 5
2026-08-26	$9.26	$4,226,179,322	5 / 5
2026-08-27	$9.26	$4,226,179,322	5 / 5
2026-08-28	$9.26	$4,226,179,322	5 / 5
2026-08-29	$9.26	$4,226,179,322	6 / 6
2026-08-30	$9.26	$4,226,179,322	6 / 6
2026-08-31	$9.26	$4,226,179,322	6 / 6
2026-09-01	$9.26	$4,226,179,322	6 / 6
2026-09-02	$9.26	$4,226,179,322	6 / 6
2026-09-03	$9.26	$4,226,179,322	6 / 6
2026-09-04	$9.26	$4,226,179,322	6 / 6
2026-09-05	$9.26	$4,226,179,322	6 / 6
2026-09-06	$9.26	$4,226,179,322	6 / 6
2026-09-07	$9.26	$4,226,179,322	6 / 6
2026-09-08	$9.29	$4,226,179,322	6 / 6
2026-09-09	$9.29	$4,226,179,322	6 / 6
2026-09-10	$9.29	$4,226,179,322	6 / 6
2026-09-11	$9.29	$4,226,179,322	6 / 6
2026-09-12	$9.29	$4,226,179,322	6 / 6
2026-09-13	$9.29	$4,226,179,322	6 / 6
2026-09-14	$9.29	$4,226,179,322	6 / 6
2026-09-15	$9.29	$4,226,179,322	6 / 6
2026-09-16	$9.29	$4,226,179,322	6 / 6
2026-09-17	$9.29	$4,226,179,322	6 / 6
2026-09-18	$9.29	$4,226,179,322	6 / 6
2026-09-19	$9.29	$4,226,179,322	6 / 6
2026-09-20	$9.29	$4,226,179,322	6 / 6
2026-09-21	$9.29	$4,226,179,322	6 / 6
2026-09-22	$9.29	$4,226,179,322	6 / 6
2026-09-23	$9.29	$4,226,179,322	6 / 6
2026-09-24	$9.29	$4,226,179,322	6 / 6
2026-09-25	$9.23	$4,224,450,751	6 / 6
2026-09-26	$9.23	$4,224,450,751	6 / 6
2026-09-27	$9.23	$4,224,450,751	6 / 6
2026-09-28	$9.23	$4,224,450,751	6 / 6
2026-09-29	$9.23	$4,224,450,751	6 / 6
2026-09-30	$9.23	$4,224,450,751	6 / 6
2026-10-01	$9.23	$4,224,450,751	6 / 6
2026-10-02	$9.23	$4,224,450,751	6 / 6
2026-10-03	$9.23	$4,224,450,751	6 / 6
2026-10-04	$9.23	$4,224,450,751	6 / 6
2026-10-05	$9.23	$4,224,450,751	6 / 6
2026-10-06	$9.23	$4,224,450,751	6 / 6
2026-10-07	$9.23	$4,224,450,751	6 / 6
2026-10-08	$9.23	$4,224,450,751	6 / 6
2026-10-09	$9.23	$4,224,450,751	6 / 6
2026-10-10	$9.23	$4,224,450,751	6 / 6
2026-10-11	$9.23	$4,224,450,751	6 / 6
2026-10-12	$9.23	$4,224,450,751	6 / 6
2026-10-13	$9.23	$4,224,450,751	6 / 6
2026-10-14	$9.23	$4,224,450,751	6 / 6
2026-10-15	$9.23	$4,224,450,751	6 / 6
2026-10-16	$9.23	$4,224,450,751	6 / 6
2026-10-17	$9.23	$4,224,450,751	6 / 6
2026-10-18	$9.23	$4,224,450,751	6 / 6
2026-10-19	$9.23	$4,224,450,751	6 / 6
2026-10-20	$9.23	$4,224,450,751	6 / 6
2026-10-21	$9.23	$4,224,450,751	6 / 6
2026-10-22	$9.23	$4,224,450,751	6 / 6
2026-10-23	$9.23	$4,224,450,751	6 / 6
2026-10-24	$9.23	$4,224,450,751	6 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	5	1
2026-06-01	5	1
2026-07-01	5	1
2026-08-01	6	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Implement $200M share repurchase programDirect metric needs a verified mapping
Achieve $60M synergy cost savings in 2026Published status: Under Pressure
EPS near $4.92 in 2026Diluted EPS: $0.54 per share
Consolidated revenue growth of 5-7% in 2026Revenue growth: 4.94%

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-38.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

JBT Marel Corporation outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is an execution-dependent industrials business, not a clear durable compounder today. The long-term thesis is in a watch state: revenue growth is tracking management’s goal, but earnings quality is loss-making and recent performance sits below its industry cohort.

What's priced into JBT Marel Corporation

Valuation evidence is mixed: one measure points to JBTM being cheap versus peers, while another shows a 0.6 premium. The expectations-gap measure is negative, and the priced-in assessment is tagged justified with low fragility, so the evidence does not show a clear case of excessive expectations.

What the fundamentals likely do

Near term, revenue growth is tracking management’s 5–7% 2026 goal, while synergy savings remain a mixed execution item despite a consistent $60 million target. The company has started its repurchase program, but a recent earnings miss and a run of misses among peers are risks; the sector backdrop is also a headwind.

What JBT Marel Corporation hinges on

Over the next few quarters, avoiding a guidance cut matters because that would signal weaker execution. Delivery on the 2026 growth and synergy goals would support the multi-year thesis, while continued earnings misses would weigh on it. Results and guidance from industrial bellwethers GEV, PH, and TT could indicate whether sector conditions are improving or weakening.